वैकल्पिक उत्पाद विश्लेषण
आपकी अनुमति से हम गोपनीयता-सीमित विश्लेषण का उपयोग करके समझते हैं कि कौन-सी शोध यात्राएँ उपयोगी हैं। हम विज्ञापन ट्रैकर या सत्र रिकॉर्डिंग नहीं चलाते। आप यह विकल्प प्राथमिकताओं में बदल सकते हैं। पढ़ें गोपनीयता नीति.
Illumina, Inc.'s published Sell conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $39.1B | |
|---|---|---|
| Revenue (ttm) | 4.5B | |
| Net income (ttm) | 824M | |
| EPS (ttm) | $5.37 | |
| Shares out | 151M | |
| P/E (trailing) | 53.8x | |
| P/E (forward) | 40.3x | |
| Volume | 2,029,934 | |
| Beta | 1.42 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2022-01-02 | 2023-01-01 | 2023-12-31 | 2024-12-29 | 2025-12-28 | Trend |
| Revenue | $4.53B | $4.58B | $4.50B | $4.37B | $4.34B | -1.0% |
| Gross profit | $3.15B | $2.97B | $2.74B | $2.86B | $2.87B | -2.3% |
| Operating income | $-123.0M | $-4.18B | $-1.07B | $-833.0M | $807.0M | — |
| Net income | $762.0M | $-4.40B | $-1.16B | $-1.22B | $850.0M | +2.8% |
| EPS (diluted) | $4.90 | $-28.00 | $-7.34 | $-7.69 | $5.45 | +2.7% |
| EBITDA | $128.0M | $-3.79B | $-1.07B | $-725.0M | $1.46B | +83.7% |
| R&D | $1.19B | $1.32B | $1.35B | $1.17B | $967.0M | -5.0% |
| SG&A | $2.09B | $1.30B | $1.61B | $1.09B | $1.09B | -15.1% |
Recent company headlines from major financial publishers.
The modal base path reflects management's FY2026 guidance for reported revenue and operating margin. Clinical consumables expansion at mid-teens offsets mid-to-high single-digit research declines. This trajectory generates Fair value of $119.53, implying -53.9% return relative to $259.19.
In the Bull case, clinical sequencing expands rapidly across oncology and rare disease diagnostics, driving mid-teens clinical consumables growth and enabling FY2027 revenue to reach high single digits. Operating margins expand via high consumable pull-through, supporting Potential value of $146.73. Notably, even this optimistic outcome remains well below $259.19.
| Ke ↓ / g → | 2.0% | 2.5% | 3.0% | 3.5% | 4.0% |
|---|---|---|---|---|---|
| 9.3% | $122 | $124 | $127 | $129 | $132 |
| 9.8% | $119 | $121 | $123 | $125 | $127 |
| 10.3% | $116 | $118 | $120 | $121 | $124 |
| 10.8% | $114 | $115 | $117 | $118 | $120 |
| 11.3% | $111 | $113 | $114 | $115 | $117 |
Upcoming earnings date and setup when available.
हर महीने प्रकाशित शोध संस्करण की रेटिंग। रेटिंग विश्लेषण की तारीख की कीमत की तुलना उचित मूल्य से करती है; यह इस बात का रिकॉर्ड नहीं है कि आकलन सही निकला या नहीं।
| वर्ष | जन॰ | फ़र॰ | मार्च | अप्रैल | मई | जून | जुल॰ | अग॰ | सित॰ | अक्टू॰ | नव॰ | दिस॰ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
